Figure 7: Effects of YKL-05-093 administration on bone gene expression in vivo.
From: SIKs control osteocyte responses to parathyroid hormone
(a,b) Male mice of 8 week age C57B/6 (n=4 per group) were treated with the indicated dose of YKL-05-093 via intraperitoneal injection. After 2 h, bone RNA was isolated and transcript abundance was measured by RT-qPCR. # indicates P<0.05 versus vehicle and * indicates P<0.01 versus vehicle by student’s unpaired two tailed t-test. (c) Left: sclerostin immunohistochemistry was performed 2 h after intraperitoneal injection with either vehicle or YKL-05-093 (20 μmol kg−1). Right: quantification of sclerostin-positive cortical osteocytes, n=4 mice per treatment group, * indicated P<0.01 versus vehicle. Scale bar, 40 μm. (d–i) Genes regulated by PTH and YKL-05-093 in vitro are also regulated by YKL-05-093 in vivo. Male mice were treated with YKL-05-093 (20 μmol kg−1) and bone RNA collected 2 h later as in a. *indicates P<0.05 versus vehicle.
